BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 27085680)

  • 1. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
    Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
    Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
    Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
    Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
    Kim EC; Park J; Noh G; Park SJ; Noh K; Kwon IK; Ahn SJ
    Bioelectromagnetics; 2018 Jul; 39(5):394-404. PubMed ID: 29709064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression.
    Cheon YH; Baek JM; Park SH; Ahn SJ; Lee MS; Oh J; Kim JY
    BMC Complement Altern Med; 2015 Aug; 15():280. PubMed ID: 26271279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iguratimod prevents ovariectomy‑induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator‑activated receptor‑γ.
    Wu YX; Sun Y; Ye YP; Zhang P; Guo JC; Huang JM; Jing XZ; Xiang W; Yu SY; Guo FJ
    Mol Med Rep; 2017 Dec; 16(6):8200-8208. PubMed ID: 28983607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
    Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
    Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethanol extract of Polyscias fruticosa leaves suppresses RANKL-mediated osteoclastogenesis in vitro and LPS-induced bone loss in vivo.
    Tran PT; Dang NH; Kim O; Van Cuong P; Dat NT; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Jun; 59():152908. PubMed ID: 30981187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
    Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
    Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
    Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
    Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.
    Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y
    PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB.
    Quan GH; Wang H; Cao J; Zhang Y; Wu D; Peng Q; Liu N; Sun WC
    Int J Mol Sci; 2015 Dec; 16(12):29496-507. PubMed ID: 26690415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
    Abdallah BM; Ali EM; Elsawy H; Badr GM; Abdel-Moneim AM; Alzahrani AM
    Biomed Res Int; 2019; 2019():9395146. PubMed ID: 31976330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.